Anosmia Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Anosmia Market is segmented By Type (Idiopathic Anosmia, Congenital Anosmia, Others), By Treatment Type (Medications, Decongestants, Antihistamines, Steroid Nasal Sprays, Therapies, Others), By End User (Hospitals, Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share Outlook, and Opportunity Analysis, 2024-2031

Anosmia Market Overview

The Global Anosmia Market is estimated to reach at a high CAGR during the forecast period (2024-2031).

Anosmia is a partial or total loss of sense of smell. This loss may be temporary or permanent. Some common conditions that irritate the nose’s lining, such as allergies or a cold, can lead to temporary Anosmia. Anosmia is frequently caused by swelling or blockage in the nose parts that prevents odors from getting to the top of the nose and also sometimes it is caused by a problem with the nervous system that sends signals from the nose to the brain. More serious conditions that affect the brain or nerves, such as brain tumors or head trauma, can cause permanent loss of smell. Old age sometimes causes Anosmia. Some symptoms include Inability to smell, Inability to taste, Stuffy nose and congestion, Persistent sneezing, nasal drainage, itchy, watery eyes, Weight loss, Headaches, Nose Bleeds. Treatments include medications and therapies.

Anosmia Market Scope

For More Insights - Request Free Sample

Anosmia Market Dynamics

The global anosmia market growth is driven by the increasing incidence of anosmia cases, rising research activities for new drug developments, growing healthcare expenditure are the major factors.

The increasing incidence of anosmia cases is expected to drive the global Anosmia market during the forecast period.

Anosmia is a partial or total loss of sense of smell. For instance, an article published by the ENT UK at The Royal College of Surgeons of England in 2020, reports that the novel COVID-19 virus causes anosmia in infected patients. Moreover, the same source, ENT UK at The Royal College of Surgeons of England in 2020, also reports that 30% of patients in South Korea, had anosmia. Similarly, according to the same source in Germany, it is reported that more than 2 in 3 confirmed cases have anosmia. In the United States, 3% of people aged over 40 are affected by anosmia.

Rising research activities for new drug developments is expected to drive the global Anosmia market during the forecast period.

Growing research activities by the market players to develop a novel treatment for anosmia is expected to drive the global anosmia market growth over the forecast period. For instance, in June 2019, Washington University School of Medicine, started the Phase II study, to evaluate the efficacy and safety of Budesonide in patients with coronavirus smell therapy for anosmia recovery. The study is expected to complete in December 2023.

For instance, ClinAmygate developing for Anosmia and/or Ageusia in COVID-19 Treatment with Early Corticosteroid (Dexamethasone) and Recovery is under Phase 4 clinical trials which will increase the demand for the anosmia market.

Lack of approved drugs or therapeutics for anosmia are likely to restrict the market growth

Lack of approved drugs or therapeutics for anosmia is the major factor expected to hamper the market growth. Currently, decongestants, antihistamines, and steroid nasal sprays are used off-label to treat anosmia. None has been explicitly approved for treating anosmia/hyposmia, although some have been approved to treat underlying problems, such as the use of steroid sprays for chronic nasal inflammation.

COVID-19 Impact Analysis

The covid-19 pandemic outbreak has enhanced the need to evaluate the anosmia market to treat Covid-19 infections. Chemosensory disturbances like loss of smell or taste, are the most neurological symptom of COVID-19. More than 80% of COVID-19 patients exhibit some change in chemesthesis, including smell. Anosmia has also been more common of COVID-19 than all other symptoms, including fever, cough or fatigue, based on a survey of 2 million participants in the UK and US. Google searches for "smell," "loss of smell," "anosmia," and other similar terms increasing since the early months of the pandemic and strongly correlated with increases in daily cases and deaths. Research into the mechanisms underlying these symptoms is currently ongoing. Many countries already listed anosmia as an official COVID-19 symptom, and some have developed "smell tests" as potential screening tools. For instance, in 2020, the Global Consortium for Chemosensory Research, a collaborative research organization of international smell and taste researchers, was formed to investigate the loss of smell and related chemosensory symptoms.

Anosmia Market Segment Analysis

Based on the type, the global anosmia market is segmented into Idiopathic Anosmia, Congenital Anosmia

Idiopathic anosmia refers to patients in whom, after extensive testing, no cause for the loss of sense of smell is found. This diagnosis must be made only after blood tests and brain scans have been performed. Patients in this category may go on to develop Parkinson’s and Alzheimer’s diseases. For instance, an article published by the Fifth Sense in 2020 reports that amongst the familiar smell loss disorders, idiopathic anosmia accounts for 25%, and congenital anosmia holds a share of 1% in the U.K.

Congenital Anosmia is a rare type, some people are born without a sense of smell, which is a condition called congenital anosmia. It occurs when there is either an inherited genetic disorder or abnormal development of the olfactory system (the body’s sensory system for smell) occurring before birth. But there is no cure for congenital anosmia.

Based on the treatment type, the global anosmia market is segmented into therapies (nasal endoscopy, imaging), medications (decongestants, antihistamines, steroid nasal sprays) and others

The medication’s segment accounts for the largest share of the market. Decongestant’s medications work by causing blood vessels to constrict and help to relieve congestion caused by the dilation of blood vessels in the nasal passages. Phenylephrine and phenylpropanolamine are two common drug forms. These OTC drugs can bring temporary relief from congestion.

Antihistamines work by decreasing the effects of histamine on specific cell receptors. First-generation OTC oral antihistamines, including diphenhydramine and chlorpheniramine.

Nasal corticosteroids relieve congestion by decreasing the inflammation in your nose. Unlike inhaled corticosteroids used for asthma, nasal versions are sprayed directly into the nasal passages. Nasal corticosteroids are commonly available in spray form. They’re also available as aerosol liquids and powders.

For instance, the University of Anbar developed a drug to study the effect of nasal steroids in treating anosmia due to COVID-19 disease by drug Ophtamesone is under early phase 1 trial.

Based on end-user, the global anosmia market is segmented into hospitals,  clinics, others.

Due to the growing patient population, the hospital's segment held the largest market share. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also, the surgery is done under the supervision of medical practioners at these locations.

Anosmia Market Geographical Share

North America region holds the largest market share in the global anosmia market

North America served the largest share in the global anosmia market over the forecast period, owing to increasing cases of anosmia in the region. For instance, an article published by the National Center for Biotechnology Information (NCBI) in 2017 reports that a substantial portion, i.e., around 4.3 million people, 65 years or older, suffer from anosmia U.S. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel treatments, the total availability of advanced technological tools, FDA approval of new drugs. For instance, Washington University School of Medicine conducting a Phase 2 study of Smell in Covid-19 and Efficacy of Nasal Theophylline is expected to complete by 2021.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to the increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations.

Anosmia Market Companies and Competitive Landscape

The global anosmia market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Mylan N.V., Pfizer Inc., Atom Pharma, Ranbaxy laboratories limited, Alde Medi Impex, GlaxoSmithKline plc, Sandoz (Novartis AG), Cadila Pharmaceuticals, Taj Pharmaceuticals Limited, and Sanofi. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, in June 2020, Cadila Pharmaceuticals Limited launched Bilastine syrup (30 ml) and Bilastine tablets (20 mg), an antihistamine drug. This drug is used in the treatment of allergic rhinitis, which later develops anosmia.

Pfizer Inc. 

Overview: Pfizer Inc is an American multinational pharmaceutical company established in 1849. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company’s portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

Key developments:

In 2020, Pfizer partnered with BioNTech, a German biotech firm, to study and develop COVID-19 mRNA vaccine candidates. On July 27, 2020, the companies started a global (except China) Phase 2/3 safety and efficacy clinical study to evaluate the mRNA vaccine candidate BNT162b2. The companies plan to use Pfizer facilities to manufacture the vaccine if they receive FDA approval.

Why Purchase the Report?

• Visualize the composition of the anosmia market segmentation by Type, Treatment Type, and by End-user highlighting the key commercial assets and players.
• Identify commercial opportunities in the anosmia market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of anosmia market-level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The global anosmia market report would provide access to an approx. 61 market data table, 51 figures and 180 pages. 

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers